Moreover, the kinase function appears to be the final outcome of LRRK2 signaling and is upregulated in all PD-causing mutants; therefore, from a pharmacological standpoint, this should be the most straightforward option to clinically target LRRK2. The gene discussed is LRRK2; the disease is Parkinson disease.